{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:49:16Z","timestamp":1782175756832,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["445785155"],"award-info":[{"award-number":["445785155"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["495271833"],"award-info":[{"award-number":["495271833"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR2291\/16-1"],"award-info":[{"award-number":["KR2291\/16-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR2291\/15-1"],"award-info":[{"award-number":["KR2291\/15-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["393547839 \\u2013 SFB 1361"],"award-info":[{"award-number":["393547839 \\u2013 SFB 1361"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["496927074"],"award-info":[{"award-number":["496927074"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["502534123"],"award-info":[{"award-number":["502534123"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR2291\/18-1"],"award-info":[{"award-number":["KR2291\/18-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR2291\/12-1"],"award-info":[{"award-number":["KR2291\/12-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR2291\/17-1"],"award-info":[{"award-number":["KR2291\/17-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["528202295"],"award-info":[{"award-number":["528202295"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["469954457"],"award-info":[{"award-number":["469954457"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG KR2291\/14-1"],"award-info":[{"award-number":["DFG KR2291\/14-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.biopha.2024.117076","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T22:36:47Z","timestamp":1720132607000},"page":"117076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells"],"prefix":"10.1016","volume":"177","author":[{"given":"Christoph","family":"Hieber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Hassan M.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Neuroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Henninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Wollscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Zabkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9803-2822","authenticated-orcid":false,"given":"Michelle","family":"Lazenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4391-9802","authenticated-orcid":false,"given":"Caroline","family":"Alvares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siavosh","family":"Mahboobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Butter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-6212","authenticated-orcid":false,"given":"Walburgis","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2024.117076_bib1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine Kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2024.117076_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.biopha.2024.117076_bib3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.2019876821","article-title":"Availability of FLT3 inhibitors: how do we use them?","volume":"134","author":"Perl","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2024.117076_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"issue":"10388","key":"10.1016\/j.biopha.2024.117076_bib5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"7397","key":"10.1016\/j.biopha.2024.117076_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.biopha.2024.117076_bib7","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2024.117076_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2021.10.011","article-title":"Identification of a highly efficient dual type I\/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells","volume":"29","author":"Beyer","year":"2022","journal-title":"Cell Chem. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2024.117076_bib10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2013-01-476473","article-title":"Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia","volume":"122","author":"Opatz","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2024.117076_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00277-016-2616-z","article-title":"Leukemogenic potency of the novel FLT3-N676K mutant","volume":"95","author":"Huang","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2024.117076_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112232","article-title":"A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia","volume":"193","author":"Sellmer","year":"2020","journal-title":"Eur. J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna di Rora","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.117076_bib14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharm. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2024.117076_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14728214.2017.1330885","article-title":"Emerging cell cycle inhibitors for acute myeloid leukemia","volume":"22","author":"Abou Zahr","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"7","key":"10.1016\/j.biopha.2024.117076_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tig.2013.02.003","article-title":"WEE1 tyrosine kinase, a novel epigenetic modifier","volume":"29","author":"Mahajan","year":"2013","journal-title":"Trends Genet"},{"issue":"3","key":"10.1016\/j.biopha.2024.117076_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110261","article-title":"WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity","volume":"38","author":"Elbaek","year":"2022","journal-title":"Cell Rep."},{"issue":"20","key":"10.1016\/j.biopha.2024.117076_bib18","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","article-title":"Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption","volume":"32","author":"Beck","year":"2012","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117076_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1083\/jcb.201101047","article-title":"Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease","volume":"194","author":"Dom\u00ednguez-Kelly","year":"2011","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117076_bib20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.devcel.2016.11.017","article-title":"A mechanism for controlled breakage of under-replicated chromosomes during mitosis","volume":"39","author":"Duda","year":"2016","journal-title":"Dev. Cell"},{"issue":"9","key":"10.1016\/j.biopha.2024.117076_bib21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nsmb.2356","article-title":"H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes","volume":"19","author":"Mahajan","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2024.117076_bib22","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/1535-7163.MCT-16-0660","article-title":"A Small-Molecule Inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute Leukemia","volume":"16","author":"Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biopha.2024.117076_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","article-title":"Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation","volume":"28","author":"Pfister","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2024.117076_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110996","article-title":"Inhibiting RRM2 to enhance the anticancer activity of chemotherapy","volume":"133","author":"Zhan","year":"2021","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2024.117076_bib25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2020.09.016","article-title":"Reality CHEK: understanding the biology and clinical potential of CHK1","volume":"497","author":"Neizer-Ashun","year":"2021","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.biopha.2024.117076_bib26","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.223123","article-title":"Chk1-mediated Cdc25A degradation as a critical mechanism for normal cell cycle progression","volume":"132","author":"Goto","year":"2019","journal-title":"J. Cell Sci."},{"issue":"9","key":"10.1016\/j.biopha.2024.117076_bib27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.onc.1208344","article-title":"Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype","volume":"24","author":"Neben","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib28","article-title":"Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","article-title":"Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3","volume":"96","author":"Wachholz","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2024.117076_bib30","article-title":"Phase I clinical trial of the Wee1 inhibitor adavosertib (AZD1775) with irinotecan in children with relapsed solid tumors. A COG Phase I consortium report (ADVL1312)","author":"Cole","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"29","key":"10.1016\/j.biopha.2024.117076_bib31","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.19.00730","article-title":"Dose escalation trial of the Wee1 Inhibitor Adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.biopha.2024.117076_bib32","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.20.03167","article-title":"Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/ijgc-2021-003144","article-title":"ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma","volume":"32","author":"Liu","year":"2022","journal-title":"Int J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2024.117076_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-023-04511-0","article-title":"Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies","volume":"91","author":"Shafer","year":"2023","journal-title":"Cancer Chemother. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.117076_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41375-022-01785-w","article-title":"A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients","volume":"37","author":"Massacci","year":"2023","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.biopha.2024.117076_bib36","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.biopha.2024.117076_bib37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4155\/fmc-2017-0298","article-title":"Dual FLT3\/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines","volume":"10","author":"Dayal","year":"2018","journal-title":"Future Med Chem."},{"key":"10.1016\/j.biopha.2024.117076_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-014-0053-9","article-title":"CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells","volume":"7","author":"Qi","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117076_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","article-title":"Mitochondria as multifaceted regulators of cell death","volume":"21","author":"Bock","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"21","key":"10.1016\/j.biopha.2024.117076_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115849","article-title":"AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens","volume":"24","author":"Milnerowicz","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.biopha.2024.117076_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194816","article-title":"TP53 mutation in acute myeloid leukemia: an old foe revisited","volume":"15","author":"Shin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-024-00579-9","article-title":"p53 biology and reactivation for improved therapy in MDS and AML","volume":"12","author":"Zawacka","year":"2024","journal-title":"Biomark. Res"},{"issue":"11","key":"10.1016\/j.biopha.2024.117076_bib43","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/jmcb\/mjab047","article-title":"Deciphering the PTM codes of the tumor suppressor p53","volume":"13","author":"Wen","year":"2022","journal-title":"J. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117076_bib44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.biopha.2024.117076_bib45","doi-asserted-by":"crossref","first-page":"9390","DOI":"10.1074\/jbc.275.13.9390","article-title":"Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139","volume":"275","author":"Rogakou","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2024.117076_bib46","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1751-1097.2011.00995.x","article-title":". gammaH2Ax: biomarker of damage or functional participant in DNA repair \"all that glitters is not gold!","volume":"87","author":"Cleaver","year":"2011","journal-title":"Photochem. Photobio."},{"issue":"9","key":"10.1016\/j.biopha.2024.117076_bib47","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.tips.2017.05.009","article-title":"Interstrand crosslink repair as a target for HDAC inhibition","volume":"38","author":"Nikolova","year":"2017","journal-title":"Trends Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","article-title":"Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors","volume":"13","author":"Short","year":"2023","journal-title":"Blood Cancer J."},{"issue":"6628","key":"10.1016\/j.biopha.2024.117076_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1126\/science.adg6276","article-title":"FDA no longer has to require animal testing for new drugs","volume":"379","author":"Wadman","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.117076_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020378","article-title":"BCL2L11 Induction Mediates Sensitivity to Src and MEK1\/2 inhibition in thyroid cancer","volume":"15","author":"Rose","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.biopha.2024.117076_bib52","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1158\/1078-0432.CCR-15-0279","article-title":"Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP Antiapoptotic Proteins","volume":"21","author":"Tanaka","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2024.117076_bib53","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/leu.2014.296","article-title":"A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations","volume":"29","author":"Zhou","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.biopha.2024.117076_bib54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41375-022-01795-8","article-title":"Dual inhibition of CHK1\/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.biopha.2024.117076_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143464","article-title":"Oncogenic kinase cascades induce molecular mechanisms that protect leukemic cell models from lethal effects of De Novo dNTP synthesis inhibition","volume":"13","author":"Pons","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.biopha.2024.117076_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111714","article-title":"A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells","volume":"9","author":"Taricani","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2024.117076_bib57","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-018-03096-0","article-title":"HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130","volume":"9","author":"G\u00f6der","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2024.117076_bib58","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/s41375-023-02036-2","article-title":"Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3","volume":"37","author":"Zeyn","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.biopha.2024.117076_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjh.16665","article-title":"Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia","volume":"191","author":"Zabkiewicz","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"23","key":"10.1016\/j.biopha.2024.117076_bib60","article-title":"Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells","volume":"S2090-1232","author":"Fischer","year":"2023","journal-title":"J. Adv. Res"},{"issue":"4","key":"10.1016\/j.biopha.2024.117076_bib61","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1101\/gad.364306","article-title":"Acetylation of Stat1 modulates NF-kappaB activity.","volume":"20","author":"Kr\u00e4mer","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2024.117076_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41540-019-0098-z","article-title":"Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer","volume":"5","author":"Tang","year":"2019","journal-title":"NPJ Syst. Biol. Appl."},{"issue":"8","key":"10.1016\/j.biopha.2024.117076_bib63","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/nprot.2007.261","article-title":"Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips","volume":"2","author":"Rappsilber","year":"2007","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.biopha.2024.117076_bib64","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox","year":"2008","journal-title":"Nat. Biotechnol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224009600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224009600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:20:32Z","timestamp":1782174032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224009600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":64,"alternative-id":["S0753332224009600"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117076","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117076"}}